Severe COVID-19 infection in a kidney transplant recipient treated with lopinavir/ritonavir, hydroxychloroquine and dexamethasone

• Main Authors: Satriyo Dwi Suryantoro, -, Mochammad Thaha, -, Pranawa, -, Djoko Santoso, -, Nunuk Mardiana, -, Widodo, -, Aditiawardana, -, Artaria Tjempakasari, -, Ardityo Rahmat Ardhany, -, Dana Pramudya, -, Decsa Medika Hertanto, -, Evy Febriane, -, Meryana, -, Maria Angela, -, Ari Christy Muliono, -, Handoko Tanuwidjaja, -, Philia Setiawan, -, David Sugiarto, -
• 格式: Article PeerReviewed
• 語言: English; English; English; English
• 出版: Open Learning on Enteric Pathogens 2021
• 主題: R Medicine (General); RC Internal medicine
• 在線閱讀: https://repository.unair.ac.id/112604/1/02.%20Severe%20COVID-19%20infection%20in%20a%20kidney%20transplant%20recipient%20treated%20with.pdf; https://repository.unair.ac.id/112604/2/JIDC%20-%20Kidney%20Transplant.pdf; https://repository.unair.ac.id/112604/3/2.pdf; https://repository.unair.ac.id/112604/4/Severe%20COVID-19%20infection%20in%20a%20kidney%20transplant%20recipient%20treated%20with%20lopinavir_ritonavir%2C%20hydroxychloroquine%20and%20dexamethasone.pdf; https://repository.unair.ac.id/112604/; https://jidc.org/index.php/journal/article/view/34669593; https://doi.org/10.3855/jidc.14952
• 機構: Universitas Airlangga

Severe COVID-19 infection management for a recipient of kidney transplant has debatable prognosis and treatment. We described the case of a COVID-19 infected 70 year old female, previously had renal transplantation in 2017. The patient took immunosuppressive agents as routine drugs for transplant re...